Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets

Zeria Pharmaceutical16 enrolled

Overview

The purpose of this study is to investigate the efficacy and safety of oral phosphate (Z-521) in subjects with primary hypophosphatemic rickets.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Primary Hypophosphatemic Rickets

Interventions

Z-521DRUG

Eligibility

Sex: ALLMin age: 1 YearMax age: 14 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed as primary hypophosphatemic rickets based on familial history, genetic test or laboratory test results. Exclusion Criteria: * A hyperparathyroidism

Locations (4)

Chiba Children's Hospital

Chiba, Japan

Kanagawa Children's Medical Center

Kanagawa, Japan

Osaka University Hospital

Osaka, Japan

Tokyo Metropolitan Children's Medical Center

Tokyo, Japan

Outcomes

Primary Outcomes

Serum ALP level

Time frame: 6 month

Serum phosphate level

Time frame: 6 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.